731 De novo Inflammatory Bowel Disease After Secukinumab Use: A Population Based Analysis

INTRODUCTION: Secukinumab is a human monoclonal antibody and an inhibitor of IL-17A. It is indicated for treatment of Psoriatic Arthritis, Psoriasis and Ankylosing Spondylitis. There have been a few case reports documenting new or worsening IBD in patients being treated with secukinumab. However, large patient cohorts reporting this relationship are lacking. The aim of this study is to analyze if the use of secukinumab leads to increased risk of...